Phosphodiesterase type III (PDE III) inhibitors or CA
The present invention relates to a phosphodiesterase type III (PDE III) inhibitor and/or Ca 2+ -sensitizing agent or a pharmaceutically acceptable derivative thereof for the treatment of a patient suffering from hypertrophic cardiomyopathy (HCM). According to another aspect the present invention relates to the use of a PDE III inhibitor and/or Ca 2+ -sensitizing agent for the preparation of a medicament for the treatment of a patient suffering from HCM.
1. A method of treating a feline suffering from hypertrophic cardiomyopathy, the method comprising administering a medicament comprising an effective amount of pimobendan to a feline suffering from hypertrophic cardiomyopathy, the effective amount of pimobendan being a daily dosage of from 10 μg/kg feline bodyweight to 1500 μg/kg feline bodyweight.
2. The method of claim 1 , wherein said administering the medicament comprises oral administration of the medicament.
3. The method of claim 1 , wherein said administering the medicament comprises parenteral administration of the medicament.
4. The method of claim 1 , wherein said daily dosage is between 20 to 250 micrograms of pimobendan per kilogram of the feline's bodyweight.
5. The method of claim 1 , wherein said administering the medicament further comprises administering the medicament together with furosemide.
6. The method of claim 5 , wherein the furosemide is administered in a dosage between 0.5 to 5 milligrams of furosemide per kilogram of the feline's bodyweight once or twice daily.
7. The method of claim 5 , wherein the furosemide is administered parenterally.
8. The method of treating a feline according to claim 1 , wherein the medicament is administered once in a 24 hour period.
9. The method of treating a feline according to claim 1 , wherein the daily dosage is administered in two doses within a 24 hour period.
10. The method of treating a feline according to claim 1 , wherein the method comprises a two phase combination therapy including:
administering daily a first medicament comprising the effective amount of pimobendan in combination with an effective amount of furosemide for a first predetermined period of time; and
administering daily a second medicament comprising the effective amount of pimobendan and no furosemide for a second predetermined period of time.
11. The method of treating a feline according to claim 1 , wherein the medicament further comprises an ingredient selected from the group consisting of an L-type calcium channel blocker; a β-adrenoreceptor antagonist; and an if-blocker.
12. The method of treating a feline according to claim 1 , wherein the medicament further comprises an angiotensin-converting enzyme (ACE) inhibitor.
13. The method of treating a feline according to claim 1 , wherein the ACE inhibitor is selected from the group consisting of omapatrilat, MDL100240, alacepril, benazepril, captopril, cilazapril, delapril, enalapril, enalaprilat, fosinopril, fosinoprilat, imidapril, lisinopril, perindopril, quinapril, ramipril, ramiprilat, saralasin acetate, temocapril, trandolapril, trandolaprilat, ceranapril, moexipril, quinaprilat, and spirapril.
14. The method of treating a feline according to claim 1 , wherein the treatment is effective to increase the Ca 2+ sensitivity of cardiac contractile proteins by increasing the developed contractile force at a predetermined concentration of Ca 2+ .
15. The method of treating a feline according to claim 1 , wherein administration of the effective amount achieves a reduction of the hypertrophic cardiomyopathy.